4yqh

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (13:04, 1 March 2024) (edit) (undo)
 
(3 intermediate revisions not shown.)
Line 1: Line 1:
 +
==2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A==
==2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A==
-
<StructureSection load='4yqh' size='340' side='right' caption='[[4yqh]], [[Resolution|resolution]] 2.31&Aring;' scene=''>
+
<StructureSection load='4yqh' size='340' side='right'caption='[[4yqh]], [[Resolution|resolution]] 2.31&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[4yqh]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YQH OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4YQH FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[4yqh]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4YQH OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4YQH FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=4F7:2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE'>4F7</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.308&#8491;</td></tr>
-
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4ys7|4ys7]]</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=4F7:2-[2-(4-PHENYL-1H-IMIDAZOL-2-YL)ETHYL]QUINOXALINE'>4F7</scene>, <scene name='pdbligand=MG:MAGNESIUM+ION'>MG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4yqh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yqh OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4yqh RCSB], [http://www.ebi.ac.uk/pdbsum/4yqh PDBsum]</span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4yqh FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4yqh OCA], [https://pdbe.org/4yqh PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4yqh RCSB], [https://www.ebi.ac.uk/pdbsum/4yqh PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4yqh ProSAT]</span></td></tr>
</table>
</table>
== Function ==
== Function ==
-
[[http://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN]] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>
+
[https://www.uniprot.org/uniprot/PDE10_HUMAN PDE10_HUMAN] Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. Can hydrolyze both cAMP and cGMP, but has higher affinity for cAMP and is more efficient with cAMP as substrate.<ref>PMID:17389385</ref>
-
<div style="background-color:#fffaf0;">
+
-
== Publication Abstract from PubMed ==
+
-
The design and synthesis of highly potent, selective orally bioavailable inhibitors of PDE10A is reported. Starting with an active compound of modest potency from a small focused screen, we were able to evolve this series to a lead molecule with high potency and selectivity versus other PDEs using structure-based design. A systematic refinement of ADME properties during lead optimization led to a lead compound with good half-life that was brain penetrant. Compound 39 was highly potent versus PDE10A (IC50=1.0nM), demonstrated high selectivity (&gt;1000-fold) against other PDEs and was efficacious when dosed orally in a rat model of psychosis, PCP-induced hyperlocomotion with an EC50 of 1mg/kg.
+
-
 
+
-
Evolution and synthesis of novel orally bioavailable inhibitors of PDE10A.,Burdi DF, Campbell JE, Wang J, Zhao S, Zhong H, Wei J, Campbell U, Shao L, Herman L, Koch P, Jones PG, Hewitt MC Bioorg Med Chem Lett. 2015 May 1;25(9):1864-8. doi: 10.1016/j.bmcl.2015.03.050., Epub 2015 Mar 26. PMID:25863433<ref>PMID:25863433</ref>
+
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
==See Also==
-
</div>
+
*[[Phosphodiesterase 3D structures|Phosphodiesterase 3D structures]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Burdi, D]]
+
[[Category: Homo sapiens]]
-
[[Category: Herman, L]]
+
[[Category: Large Structures]]
-
[[Category: Wang, T]]
+
[[Category: Burdi D]]
-
[[Category: Co-crystal]]
+
[[Category: Herman L]]
-
[[Category: Inhibitor]]
+
[[Category: Wang T]]
-
[[Category: Pde10a]]
+

Current revision

2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A

PDB ID 4yqh

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/4yqh"
Personal tools